Q1/2019 3/31/2019 EPS -0.280 ZacksConsensus N/A ActVsEst N/A - N/A
NovaBay Pharmaceuticals, Inc. (NBY)
NASDAQ:AMEX Investor Relations:
novabay.com/investors
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
NBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBY alerts
High impacting NovaBay Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NBY
News
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand [Yahoo! Finance]Yahoo! Finance
- Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova BrandBusiness Wire
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) had its price target lowered by analysts at Ascendiant Capital Markets from $8.00 to $0.85. They now have a "buy" rating on the stock.MarketBeat
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
NBY
Analyst Actions
- 11/11/24 - Ascendiant Capital
NBY
Sec Filings
- 11/15/24 - Form DEFA14A
- 11/13/24 - Form DEFA14A
- 11/12/24 - Form DEFA14A
- NBY's page on the SEC website